Logo image of EGRX

EAGLE PHARMACEUTICALS INC (EGRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EGRX - US2697961082 - Common Stock

2.14 USD
-1.42 (-39.89%)
Last: 10/2/2024, 8:06:00 PM
2.28 USD
+0.14 (+6.54%)
After Hours: 10/2/2024, 8:06:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to EGRX. EGRX was compared to 530 industry peers in the Biotechnology industry. While EGRX is still in line with the averages on profitability rating, there are concerns on its financial health. EGRX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

EGRX had positive earnings in the past year.
In the past year EGRX has reported a negative cash flow from operations.
EGRX Yearly Net Income VS EBIT VS OCF VS FCFEGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M 40M 60M 80M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.99%, EGRX belongs to the top of the industry, outperforming 94.01% of the companies in the same industry.
EGRX's Return On Equity of 4.80% is amongst the best of the industry. EGRX outperforms 94.54% of its industry peers.
EGRX has a better Return On Invested Capital (10.53%) than 95.77% of its industry peers.
The Average Return On Invested Capital over the past 3 years for EGRX is below the industry average of 18.28%.
Industry RankSector Rank
ROA 2.99%
ROE 4.8%
ROIC 10.53%
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
EGRX Yearly ROA, ROE, ROICEGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 10 20 30 40 50

1.3 Margins

Looking at the Profit Margin, with a value of 4.70%, EGRX belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
In the last couple of years the Profit Margin of EGRX has declined.
EGRX has a Operating Margin of 16.47%. This is amongst the best in the industry. EGRX outperforms 95.77% of its industry peers.
EGRX's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 69.86%, EGRX belongs to the top of the industry, outperforming 84.33% of the companies in the same industry.
In the last couple of years the Gross Margin of EGRX has declined.
Industry RankSector Rank
OM 16.47%
PM (TTM) 4.7%
GM 69.86%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
EGRX Yearly Profit, Operating, Gross MarginsEGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), EGRX is creating some value.
Compared to 1 year ago, EGRX has more shares outstanding
Compared to 1 year ago, EGRX has a worse debt to assets ratio.
EGRX Yearly Shares OutstandingEGRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
EGRX Yearly Total Debt VS Total AssetsEGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 1.81 indicates that EGRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
EGRX has a better Altman-Z score (1.81) than 70.07% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that EGRX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.25, EGRX is not doing good in the industry: 68.84% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.81
ROIC/WACC1.32
WACC7.97%
EGRX Yearly LT Debt VS Equity VS FCFEGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.3 Liquidity

EGRX has a Current Ratio of 2.16. This indicates that EGRX is financially healthy and has no problem in meeting its short term obligations.
EGRX has a Current ratio of 2.16. This is in the lower half of the industry: EGRX underperforms 75.35% of its industry peers.
EGRX has a Quick Ratio of 1.67. This is a normal value and indicates that EGRX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of EGRX (1.67) is worse than 79.58% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 1.67
EGRX Yearly Current Assets VS Current LiabilitesEGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

EGRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.52%.
The Earnings Per Share has been growing by 14.81% on average over the past years. This is quite good.
Looking at the last year, EGRX shows a decrease in Revenue. The Revenue has decreased by -5.40% in the last year.
The Revenue has been growing slightly by 5.99% on average over the past years.
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%

3.2 Future

Based on estimates for the next years, EGRX will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.47% on average per year.
Based on estimates for the next years, EGRX will show a small growth in Revenue. The Revenue will grow by 0.24% on average per year.
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EGRX Yearly Revenue VS EstimatesEGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
EGRX Yearly EPS VS EstimatesEGRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.46, which indicates a rather cheap valuation of EGRX.
Compared to the rest of the industry, the Price/Earnings ratio of EGRX indicates a rather cheap valuation: EGRX is cheaper than 99.82% of the companies listed in the same industry.
EGRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.19.
EGRX is valuated cheaply with a Price/Forward Earnings ratio of 0.64.
Based on the Price/Forward Earnings ratio, EGRX is valued cheaper than 99.65% of the companies in the same industry.
EGRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.88, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 0.46
Fwd PE 0.64
EGRX Price Earnings VS Forward Price EarningsEGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

EGRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. EGRX is cheaper than 99.12% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.31
EGRX Per share dataEGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as EGRX's earnings are expected to decrease with -26.94% in the coming years.
PEG (NY)N/A
PEG (5Y)0.03
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EGRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EAGLE PHARMACEUTICALS INC

NASDAQ:EGRX (10/2/2024, 8:06:00 PM)

After market: 2.28 +0.14 (+6.54%)

2.14

-1.42 (-39.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2024-08-06/amc
Earnings (Next)11-04 2024-11-04/amc
Inst Owners66.05%
Inst Owner Change0%
Ins Owners5.97%
Ins Owner Change0%
Market Cap27.80M
Revenue(TTM)257.50M
Net Income(TTM)12.10M
Analysts85.71
Price Target17.34 (710.28%)
Short Float %0.37%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.91%
Min EPS beat(2)10.18%
Max EPS beat(2)17.65%
EPS beat(4)4
Avg EPS beat(4)19.72%
Min EPS beat(4)10.18%
Max EPS beat(4)29.93%
EPS beat(8)5
Avg EPS beat(8)-2.39%
EPS beat(12)8
Avg EPS beat(12)72.12%
EPS beat(16)11
Avg EPS beat(16)63.08%
Revenue beat(2)2
Avg Revenue beat(2)4.74%
Min Revenue beat(2)2.71%
Max Revenue beat(2)6.76%
Revenue beat(4)3
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-7.39%
Max Revenue beat(4)6.76%
Revenue beat(8)3
Avg Revenue beat(8)-9.26%
Revenue beat(12)5
Avg Revenue beat(12)-7.18%
Revenue beat(16)5
Avg Revenue beat(16)-7.22%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.46
Fwd PE 0.64
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.28
EV/EBITDA 1.31
EPS(TTM)4.66
EY217.76%
EPS(NY)3.34
Fwd EY155.86%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS19.82
BVpS19.4
TBVpS7.67
PEG (NY)N/A
PEG (5Y)0.03
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 2.99%
ROE 4.8%
ROCE 13.33%
ROIC 10.53%
ROICexc 11.06%
ROICexgc 22.27%
OM 16.47%
PM (TTM) 4.7%
GM 69.86%
FCFM N/A
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
ROICexc(3y)19.91%
ROICexc(5y)21.41%
ROICexgc(3y)52.27%
ROICexgc(5y)50.12%
ROCE(3y)17.2%
ROCE(5y)17.09%
ROICexgc growth 3Y46.01%
ROICexgc growth 5Y-6.15%
ROICexc growth 3Y27.58%
ROICexc growth 5Y-11.05%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
F-Score3
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 0.98
Cap/Depr 0.34%
Cap/Sales 0.03%
Interest Coverage 10.44
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 1.67
Altman-Z 1.81
F-Score3
WACC7.97%
ROIC/WACC1.32
Cap/Depr(3y)10.4%
Cap/Depr(5y)10.3%
Cap/Sales(3y)0.21%
Cap/Sales(5y)0.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
EBIT growth 1Y-45.5%
EBIT growth 3Y67.47%
EBIT growth 5Y4.32%
EBIT Next Year-37.58%
EBIT Next 3Y-26.19%
EBIT Next 5YN/A
FCF growth 1Y-121.43%
FCF growth 3Y-2.92%
FCF growth 5Y-1.22%
OCF growth 1Y-120.96%
OCF growth 3Y-3.25%
OCF growth 5Y-2.96%

EAGLE PHARMACEUTICALS INC / EGRX FAQ

What is the fundamental rating for EGRX stock?

ChartMill assigns a fundamental rating of 4 / 10 to EGRX.


What is the valuation status of EAGLE PHARMACEUTICALS INC (EGRX) stock?

ChartMill assigns a valuation rating of 6 / 10 to EAGLE PHARMACEUTICALS INC (EGRX). This can be considered as Fairly Valued.


What is the profitability of EGRX stock?

EAGLE PHARMACEUTICALS INC (EGRX) has a profitability rating of 7 / 10.


What are the PE and PB ratios of EAGLE PHARMACEUTICALS INC (EGRX) stock?

The Price/Earnings (PE) ratio for EAGLE PHARMACEUTICALS INC (EGRX) is 0.46 and the Price/Book (PB) ratio is 0.11.


Can you provide the financial health for EGRX stock?

The financial health rating of EAGLE PHARMACEUTICALS INC (EGRX) is 3 / 10.